Introduction: Patients with cirrhosis and men have been under-represented in most studies examining the clinical benefit of response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC)
1 UDCA inhibits the absorption of cholesterol in the intestine and the secretion of cholesterol into bile, decreasing biliary cholesterol saturation
Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines J Hepatol
2009
Some randomised clinical trials have found an effect of ursodeoxycholic acid for primary biliary cirrhosis
Ursodeoxycholic acid is the priority drug of primary biliary cirrhosis (PBC) and is usually combined with traditional Chinese medicine
Ursodeoxycholic acid (UDCA) is a choleretic and hydrophilic endogenous bile acid that was initially developed for treating bile stones
It reported that the combination of fenofibrate and UDCA can improve the clinical indices in these patients
Ursodeoxycholic acid is the only proven therapy for PBC and in most cases can delay or prevent disease progression
This study aimed to systematically evaluate the benefits of integrated Chinese
It may be seen with primary biliary cholangitis (previously referred to as primary biliary cirrhosis), primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, biliary obstruction, chronic viral hepatitis, cirrhosis, prolonged drug-induced cholestasis, and inherited cholestasis syndromes (eg, progressive familial intrahepatic Background and aims: The therapeutic potential of ursodeoxycholic acid (UDCA) treatment in primary biliary cirrhosis (PBC) remains controversial
Ursodeoxycholic acid (UDCA) was introduced as a first-line drug for PBC around 1990; it remarkably improved patient outcomes, leading to the nomenclature change of PBC in 2015, from primary